concept w / Shutterstock.com
The German Court of Appeal has ruled that Indianapolis-based Eli Lilly’s European “vitamin regimen” patent for lung cancer injection Alimta (pemetrexed disodium) would not be infringed by Actavis’s generic version.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
German Court of Appeal, Eli Lilly, Alimta, Actavis, vitamin regimen patent, patent infringement
